We’re returning to the basics of rising new placements and the ensuing recurring income in and out of doors the U.S. with goal. It has been nearly 8 weeks since saying the termination of the Alcon transaction and the progress we have made in that quick time provides us trigger for optimism over what the long run holds for LENSAR. As I shared on our fourth quarter name, we proceed to consider strongly in our means to ship worth over the long run for all of our key stakeholders, together with our surgeon companions within the U.S., worldwide distributor companions. Let’s not overlook concerning the sufferers that our end-user companions serve and finally, our shareholders.
In parallel with these efforts to finish this organizational and thoughts reset, we’re working diligently to return to the extent of development we have been having fun with pre-transaction. We’re taking a matter-of-fact, business-as-usual method with a really clear path ahead and a eager concentrate on rebuilding momentum all through the enterprise, and I am happy to share that we’re making some nice progress. We generated complete income of $13.4 million within the quarter, which was down about 5% from $14.2 million a yr in the past. That decline, nevertheless, was a results of decrease system capital gross sales, down roughly $1.8 million year-over-year versus the position income. This was partially offset by elevated process income pushed by continued development in world process volumes.
One of the necessary takeaways I would like to spotlight from this quarter’s monetary efficiency was the continued development in our recurring income, which was up $1.1 million, or 9%, in comparison with the primary quarter of 2025, representing 94% of our complete income for Q1 2026. We count on recurring income development in 2 methods. The primary is to extend as we start once more to develop the put in base of ALLY. The second necessary initiative is to proceed to leverage our present put in base to develop recurring income pushed by the materially industry-leading utilization charges of the ALLY System. As system installations and base ramp again up, procedure-based recurring income will speed up additional.
Within the coming quarters, I look ahead to monitoring and updating you on this regard. We positioned 7 ALLY techniques through the quarter, bringing our ALLY put in base to 205 techniques roughly, with one other 11 techniques in backlog pending set up. The overall put in base of ALLY and LLS techniques reached roughly 440, up 12% in comparison with March 31, 2025. ALLY now accounts for practically half of our world put in base, demonstrating the robust adoption we proceed to see for our next-generation platform. It is necessary to acknowledge that this development within the ALLY put in base has been achieved regardless of restricted contribution from our OUS markets the previous yr.
As I identified on the final name, the preliminary ALLY launch outdoors the U.S. was very profitable, however the momentum that we have been constructing got here to a halt simply as rapidly because it began given the uncertainty over the post-acquisition enterprise integration and ALLY distribution plan ahead. Whereas complexities across the go-forward industrial dynamic created a headwind for us, doctor curiosity in ALLY and its quite a few advantages have by no means subsided. Now that we and our distributors have readability, I am assured we are able to rebuild the robust worldwide presence over time. So whereas placement exercise within the quarter was down, I need to draw consideration to the extra necessary story, which is the continued energy within the recurring income.
We’re reaching an inflection level the place the scale of our put in base is more and more supportive of the recurring income development even during times of slower system placements. That represents materially a a lot stronger and extra sturdy enterprise mannequin than the one we had within the early days of the ALLY launch. Process quantity additionally continued to development in the appropriate path. We carried out roughly 54,000 procedures within the first quarter, up from about 52,000 final yr and 39,000 in 2024.
Our U.S. process market share on the finish of the primary quarter was 23.4%, in keeping with reported market share on December 31 and anticipated given the less laser installations in This fall ’25 and Q1 2026, which generate share development for LENSAR. I consider that we are going to get again to the latest development of quarter-to-quarter market share good points transferring ahead as we proceed to transform aggressive system customers and appeal to further femto-naive surgeons into the ALLY ecosystem. My robust conviction is grounded in firsthand observations from the sector.
LENSAR has maintained a presence on the key ophthalmology conferences and with the data that we are going to be transferring ahead as an unbiased firm, our attendance at these key {industry} congresses is predicted to return to pre-acquisition ranges. Whereas our sales space on the ASCRS Annual Assembly final month in Washington, D.C. was smaller than we have had traditionally, it was no much less productive. As you understand, these conferences are deliberate months prematurely, and we had valuable little time or the chance to develop our footprint as an unbiased firm following the choice to terminate the merger.
Though we did not have prime actual property within the exhibition corridor and total assembly attendance was decrease than earlier conferences, sales space visitors was extremely excessive, which resulted in additional than 50 system demos. That is a terrific indicator of curiosity and engagement from potential surgeon companions and a really encouraging method to reinitiate LENSAR’s presence at these necessary {industry} occasions. I am actually pleased with what our workforce completed on the ASCRS, pulling it along with such professionalism and satisfaction in a matter of weeks, and I look ahead to a extra seen presence on the upcoming main conferences.
This convention was a vibrant spot and everybody on the workforce is reenergized as the keenness and curiosity in the advantages of ALLY was reaffirmed for our whole group. Whereas the workflow and follow effectivity advantages of ALLY are well-known all through the neighborhood, we see a major alternative to proceed constructing upon the strong physique of scientific proof supporting that ALLY allows surgeons to persistently ship optimum outcomes for sufferers. Within the coming months, we’ll have podium presence at a number of key {industry} congresses with ALLY persevering with to symbolize a number one voice within the ongoing scientific discourse round the advantages of laser-assisted cataract surgical procedure to surgeons, their employees, and the sufferers that they serve.
Earlier than wrapping up my ready remarks, I would wish to rapidly share a latest interplay with one in all our surgeon companions, a mirrored image — an ideal reflection of why we’re so enthusiastic and optimistic by what the long run holds for LENSAR. I’ve recognized this specific physician for years. She was utilizing a competitor’s first-generation laser and combating the inefficiencies of that know-how. She had reached some extent the place she was contemplating stopping laser-assisted cataract procedures altogether as a result of she simply could not justify the price of premium surgical procedures for her sufferers given the restricted profit she was realizing with this aggressive system. Her facility finally upgraded to an ALLY System and noticed the distinction nearly instantly.
Primarily based on early expertise, this included not solely improved efficiencies, but additionally the outcomes and increasing to enhancing the affected person expertise of their cataract process. With ALLY, her perspective on laser-assisted cataract surgical procedure modified utterly, and she or he is now recommending it to all of her sufferers. I spoke with the surgeon in a latest customers name that we had, and the feedback she made was fairly telling. She mentioned, “Nick, I’ll by no means do one other premium process with out utilizing ALLY. ” For us, that basically captures what that is actually all about, delivering on the promise of our know-how. ALLY is not merely an incremental step ahead.
It improves the expertise for all surgeons and their means to optimize remedy for premium cataract sufferers. The massive gamers in our {industry} who thought they’d be consuming our lunch are as a substitute attempting to catch up. We welcome their developments, which little question convey higher consideration to the market, and we look ahead to not solely sustaining but additionally extending our technological lead. I am going to now flip the decision over to our CFO, Tom Staab, to cowl the monetary highlights for the quarter. However earlier than doing so, I would wish to acknowledge that after right now’s name, Tom will likely be leaving us and going again to his biotech roots in addition to finding nearer to his dwelling.
On behalf of the complete group, I would wish to thank him for the 6-plus years he served alongside me and the quite a few contributions he is made to assist us get to the purpose we’re at right now. He is been a trusted colleague and an expensive buddy, and I want him the easiest as he begins his subsequent chapter. Tom?
Thomas Staab: Thanks, Nick, on your form phrases, and good morning, everyone. Earlier than I start, I would wish to thank the complete LENSAR workforce for six unimaginable years. It has been a rewarding expertise launching ALLY and serving to develop the corporate to its present state with recurring income annualizing over $50 million and ALLY persevering with to reign over all different inferior first-generation lasers. LENSAR’s future is vibrant, and I depart the group in a powerful place to reclaim the success we skilled in 2024. I look ahead to watching LENSAR construct momentum and advance its mission of delivering next-generation care in refractive cataract surgical procedure.
With that, let me flip to a short dialog of our monetary outcomes for the primary quarter, and there are only some objects to debate in higher element. Our complete income for the primary quarter of 2026 was $13.4 million in contrast with $14.2 million within the first quarter of ’25. The year-over-year decline was primarily attributable to decrease system income, which was partially offset by continued development in recurring income. System income was roughly $800,000 this quarter in contrast with $2.6 million within the prior yr quarter, reflecting decrease placement exercise from our acquisition malaise Nick mentioned earlier.
Recurring income continued to be the brilliant spot in our efficiency with complete recurring income of $12.6 million, up 9% from the $11.5 million within the prior yr quarter. Gross margin for the primary quarter was roughly $6.4 million or 48% of income in comparison with $7.1 million or 50% within the first quarter of 2025. Our gross margin proportion is squarely within the vary of 46% to 49% mentioned in our fiscal ’25 outcomes name and as mentioned then, displays the upper price of manufacturing related to inflationary improve and tariffs that we have now chosen to not cross on to our prospects. Whole working bills have been $4.1 million in contrast with $12.9 million within the first quarter of final yr.
Particularly, SG&A bills declined considerably to $2.5 million from $11.1 million, primarily attributable to a credit score of $4.4 million related to unpaid acquisition prices that have been eradicated or written off by concession of our acquisition advisers. Once you exclude acquisition-related prices, SG&A prices have been constant at $6.9 million for each first quarters ending March 31, ’26 and ’25. Internet revenue from the quarter was $36.3 million or $1.56 per primary share in comparison with a internet lack of $27.3 million a yr in the past.
It is necessary to notice that this quarter’s internet revenue was largely pushed by noncash objects, together with a $23.9 million achieve associated to the change in truthful worth of warrant liabilities, together with the popularity of $10 million acquisition deposit into our different revenue in our first quarter outcomes related to the termination of the acquisition. This recognition didn’t improve our money stability as funds have been already in our working accounts, however funds weren’t owned by us till the acquisition termination. Shifting on to adjusted EBITDA, which was destructive $311,000 versus a constructive $165,000 within the prior yr quarter.
We count on upon reaching a rebound of our quarterly placements to see our adjusted EBITDA will return to constructive territory and thereby once more generate money from operations. We ended the quarter with $13.5 million in money, money equivalents and investments, and we proceed to handle our liquidity rigorously whereas we cautiously rebuild our enterprise and hold ALLY because the premier robotic laser within the market. That concludes my feedback. And now I would like to show the decision over to Jonathan, and we look ahead to answering your questions.
Operator: And our first query for right now comes from the road of Frank Takkinen from Lake Avenue Capital Markets.
Frank Takkinen: Tom, want you the perfect. Congrats in your transition. I hoped to start out with simply an replace on type of present state of affairs. I do know we have talked about quite a lot of completely different stuff you’re rebuilding, Nick, from inside on the U.S. facet in addition to OUS with distributors. I used to be simply hoping to get a normal replace on how all of that’s going after which the first purpose of type of attending to when can the enterprise get again to a few of the prior development charges we have seen primarily based on the progress you’ve got made up to now?
Nicholas Curtis: Sure. Thanks, Frank. I hope you are doing nicely right now. I respect your query. So we have been doing precisely that. You and I had an opportunity to fulfill at ASCRS, and we talked about a few of this. I have been assembly with — and I’ve met individually with every of our distributors. We’re getting individuals again on board. I do not need to say an excessive amount of, however we have now obtained buy orders from our distributors, which could be very constructive as a result of that signifies that they are getting again on monitor and have orders. We must always ship some techniques this quarter outdoors U.S., which would be the first time in a couple of yr. So optimistic about that and restarting that enterprise.
And we have got some POs that may take us into the fourth quarter as nicely right here. So I am optimistic about that. Exercise, these 50 demos, and we did a convention name as nicely. We did like a Webex. We had about 77 individuals on that Webex simply to speak about LENSAR’s going-forward plan and technique. And the medical doctors could not have been extra supportive of the corporate and our initiatives there. And peer-to-peer exercise could be very robust. We have some conferences developing this summer time. And I would say that I am fairly happy with the exercise that we have and the rise in exercise that we have seen within the U.S. put up termination of the deal.
Frank Takkinen: That is useful. And possibly only a follow-up on that, the distributor POs. Is that one thing that is included within the backlog right now? Or was that put up quarter finish?
Nicholas Curtis: That is put up quarter finish. It should take us — simply to very succinctly, it should take us the following couple of quarters. I actually count on the following few quarters to be this like regular progress of rebuilding and enchancment right here. I feel the actually nice story is that our recurring income is so robust and that it continues to develop. And I really feel that is going to proceed. So now as we begin including further placements, I feel actually trying towards ’27 goes to be actually, actually good for us.
Frank Takkinen: Acquired it. Very useful. After which possibly only one extra for Tom can be nice to get a way of how we should always take into consideration working expense. Is that $6.9 million adjusted determine, how we ought to be excited about that for quarters transferring ahead in 2026? After which if you happen to might refresh us on type of money use expectations as we work by the transition and get again to development and profitability.
Thomas Staab: Sure. Good query, Frank. And the best method to answer your query is over the past 12 months, we have type of not rebuilt our human useful resource system. And so we’ll — and a few of our individuals have left the considering that the Alcon was going to take the reins and went to different alternatives. And so our SG&A bills are literally going to extend now organically from the $6.9 million. Clearly, we had acquisition prices in there, and we cannot have any of these going ahead. However we have to construct our service and buyer utility specialists in addition to our regional gross sales representatives to assist the expansion that we’ll do.
However we’ll do it judiciously as we go ahead. And so I feel one of the simplest ways to have a look at this and as you replicate on the fourth quarter, our system placements have been down, however it was just because we had no placements within the first quarter outdoors the US versus we had 8 placements within the quarter of first quarter of ’25. In order that’s an enormous governor on our enterprise once we have been being so profitable outdoors the US. And as Nick’s feedback allude to, we’re simply getting these distributors again on board, and so they’re excited to get again on board, however it’s not one thing that you just simply flip on a light-weight swap.
And in order we improve these variety of gross sales, then we’ll commit that money again to the enterprise. And we’re in a powerful monetary place proper now, however we do need to be even handed in how rapidly we construct simply due to paying the transaction prices and due to getting the distributors again within the saddle. And so the excellent news, as you examine the primary quarters of ’25 to ’26 in the US, we really elevated placements in the US. And in order that’s a very good factor. So all indicators, as Nick talked about, are that we’ll develop the enterprise.
It simply could take a few quarters for the distributors to get again on the horse and for the U.S. enterprise primarily based on the gross sales cycle to get again to the place we have been in 2024.
Operator: And our subsequent query comes from the road of Ryan Zimmerman from BTIG.
Ryan Zimmerman: Tom, nice working with you these previous few years and revel in being again within the Carolinas. I need to simply type of decide up quite a lot of issues. And so one of many issues is if you happen to return to first quarter ’25, you guys had very robust process development. So it was a tricky comp this quarter. However Nick, are you able to discuss each the U.S. — like parse out the U.S. versus worldwide process development this quarter relative to possibly what you noticed in first quarter ’25. After which the second query is simply I respect you are not giving steering. It is a very distinctive dynamic by way of type of getting issues going put up the transaction.
However assist us with some broad strokes about how you concentrate on the tempo of restoration as we take into consideration each procedures and recurring income and system placements. And once more, I acknowledge the problem of it, however the way you see that taking part in out over the course of the yr, I feel, can be useful.
Nicholas Curtis: Are you able to hear me? I am sorry.
Ryan Zimmerman: Sure. Now we are able to hear you, sir.
Nicholas Curtis: Okay. Nice. So I respect the considerate query right here. So whether or not — we have talked somewhat bit about this earlier than, however I am going to give somewhat colour to it and the way it pertains to now. Once you — once we set up a system, because of the coaching and the mixing of the — particularly in the event that they’re transferring it into the OR for the primary time and studying learn how to do totally sterile procedures, so on and so forth with the system, we take a look at about 30 to 90 days to type of — relying on the account and their expertise and whether or not we have now a fewer variety of surgeons or a bigger variety of surgeons to get educated.
Clearly, it takes longer with a better quantity, and it might be far more concentrated with a fewer variety of surgeons which are performing the amount in any given facility. So it takes 30 to 90 days to essentially to ramp up a system the place they’re doing productive process income, if you’ll. So in present put in base, it is best to take into consideration the — the place we speak concerning the 7 techniques within the first quarter, 11 on backlog, these techniques will begin to be put in. And from the fourth quarter now, these techniques are beginning to produce in the best way of paid techniques. So recurring income type of comes somewhat bit in waves from the expansion facet of it.
And so new techniques will convey utterly contemporary income. Present techniques will develop however will develop at a slower fee. And what we see on common is — as in comparison with a aggressive system, on common, we carry out, that is MarketScope information now, 27% larger process numbers on common than — and I alluded to this in my remarks, than a aggressive system that is been put in. And we see about an 11% improve if we’re upgrading from an LLS to an ALLY as nicely, someplace round 11% improve in procedures. And so take the brand new techniques and mission these out 30 to 90 days from the income improve perspective.
And in order we begin to get extra placements into the sector, that recurring income begins to develop somewhat extra exponentially. And that is why I am being very cautious concerning the subsequent 2 quarters as a result of we’re simply getting again to the purpose the place now individuals know who they’re coping with. And they also’re getting again to that decision-making referring to putting in of the techniques. And so 27% improve over aggressive units on common and about 11% on upgrades. And so cataract volumes in 2025 and heading into 2026 have been considerably flat in total cataract volumes.
And subsequently, as you see, simply with the bigger firms which are promoting the premium lenses, — in the event that they have not taken market share from one of many different firms, you see pretty flat numbers from them. So we’re really doing fairly nicely from a process and integration perspective as soon as we get it. However remember that little little bit of a lag. In OUS, the place we acknowledge income instantly upon promoting of a system when it leaves LENSAR completely different than income recognition within the U.S. In order we see some techniques go there, we’ll acknowledge income instantly on that, however an analogous time from — on the ramp-up of procedures there as nicely to what you see right here.
And process numbers have been fairly robust outdoors U.S., which really has been a nice shock with the present techniques which are in. In order we begin getting extra techniques on the market, I would count on to get somewhat bump there, too.
Ryan Zimmerman: Very useful, Nick. And if we return, and this goes again even while you guys got here out of PDL BioPharma, the intent of the system was to do a mixed femto and phaco, proper? And we lived by the early dynamics with FDA, et cetera. However now as you guys type of refocus the corporate, what’s your ideas across the know-how — the ALLY know-how itself? I imply, what do you need to do with it? What enhancements do you need to make? What is the type of pipeline highway map, if you’ll? As a result of we all know that the market will get extra aggressive. There are some firms creating new FLACS techniques over time right here.
And so how do you maintain this momentum and benefit over time, technologically talking?
Nicholas Curtis: Sure. So I really like this query as a result of that is actually — I really feel, particularly as an unbiased firm, that is actually necessary for us on a going-forward foundation, proper? As a result of now we’re getting some crucial mass, and I talked about that in my remarks so far as the procedures are involved. And so there are a number of purposes that we’re enhancing the ALLY system. And all of this was type of placed on maintain through the transaction as a result of we did not actually know what the buying get together was going to do or not need to do or what was going to be necessary.
So now to have the ability to restart that and from a LENSAR place, I’d say that — so we’ll — I’ll discuss a few of this on the upcoming assembly on the AECOS assembly in Madrid, however I’d say that it is most likely fairly apparent that we might begin one thing like flaps and another corneal procedures. And I will not get too particular about that. I need to have the ability to make an announcement to speak to surgeons about a few of these issues once I current.
However with the system having the aptitude it does with the dual-pulse laser, we definitely have the aptitude of doing extra within the cornea than what you’ve got seen up to now. The opposite factor is that since we have now the makings of a robotic know-how right here, you will see us transfer in the direction of extra robotic operate, continued enhancement, robotic operate of the system. And suffice to say that one space that we might take a look at very carefully, and I’ll speak extra particularly about this as we go ahead can be by way of a few of the docking and the docking of the PID to make that extra automated and to make it much less surgeon-dependent however surgeon guided as we go ahead there.
On the phaco facet, I stay open-minded as a result of we have now very robust mental property across the integration of the phaco system. And so we’ll see what’s finest. Clearly, it is extremely unlikely that LENSAR goes to take the time or the useful resource to develop a phaco. That is not going to occur. However would we revisit integration? It is determined by market dynamics and type of what a deal would appear to be for us.
Thomas Staab: So I used to be simply going to deal with your process query, which is while you take a look at the process development within the quarter, it’s solely associated to U.S. exercise. So Nick and I can not — I assume we will not emphasize sufficient that when the acquisition was introduced, there was a gradual turn-off of our distributor exercise. And so that you see that in not solely process quantity, however extra importantly, in placements. And so proper now, the U.S. enterprise remains to be doing fairly nicely. However outdoors the US, you are type of like a flat line up till the exercise that Nick simply talked about.
Ryan Zimmerman: However Tom, I feel it is necessary to name out that within the 52,347 from 1Q ’25, there may be process quantity outdoors the U.S. in that comp, proper? So sure, so that you’re comping a U.S. quantity in opposition to each a U.S. and OUS quantity, simply to be clear.
Thomas Staab: What I am saying is the rise is solely related to the US as you are evaluating these numbers and that the process quantity outdoors the US was successfully flat from Q1 of ’25.
Ryan Zimmerman: Okay. Sure, I can take that offline. However simply final one for me, Nick. I imply, with Alcon terminating the settlement, they’ve this important LenSx put in base now. And I am curious, given how outdated that know-how is as of late, what the response has been from the Alcon customers who’re sitting on these older LenSx techniques. And for you guys, does that symbolize significant alternative as a result of they thought possibly they might — there was a pathway to get to LENSAR or to get to ALLY, I ought to say, excuse me. I am simply curious type of what you are listening to from these customers or that section of the market.
Nicholas Curtis: Sure. That is a very good query. There isn’t any doubt that it’s delaying surgeons selections. I like an analogy that is quite simple, like when do you purchase a brand new automobile? And when individuals consider when they will get a brand new automobile, they many instances will attempt to drive the automobile that they have till they merely — their upkeep payments get excessive, they only do not need to proceed to cope with what they’re coping with, with their older car. And I feel that is type of the place we’re attending to, and I consider we’ll get to an inflection level.
I do not need to get forward of myself right here, however we’re sure multisystem alternatives which have older know-how and particularly, in circumstances, the LenSx put in. And I feel individuals want to come back to their very own realization that regardless of an unlimited portfolio of product, arguably, that product is outdated and is getting in the direction of the top of its helpful life. So I am trying ahead to persevering with to go after these techniques. We’re fairly disciplined, although, as a result of it will not be at any price. We’re fairly disciplined about our pricing, and we’re artistic about how we are able to put a deal collectively, which is likely one of the good issues about having this be the one product that we cope with.
However at a sure level, from a pricing perspective, we convey far more effectivity. The physician can do many extra circumstances in a day than they’ll do with any of the opposite units. I am not speaking about full therapies, and so they can save time for his or her affected person, they’ll save time for themselves. That permits them to do further premium procedures that usher in a premium of income for them as nicely and better EBITDA for them and their practices and significantly with the PE teams. We should not need to compete on a worth foundation. And so — as a result of we convey larger advantages.
So there is a fantastic line there between the incumbent utilizing all of their assets to attempt to hold the incumbent in place versus at what time will they swap. And so it isn’t if, it is when.
Operator: This does conclude the question-and-answer session of right now’s program. I would like at hand this system again to Nick Curtis for any additional remarks.
Nicholas Curtis: So I actually respect everyone becoming a member of the decision right now and much more so, your continued curiosity in LENSAR. I look ahead to updating you as we proceed to make additional progress all year long and look ahead to our subsequent name.
Operator: Thanks, girls and gents, on your participation in right now’s convention. This does conclude this system. Chances are you’ll now disconnect. Good day.
Must you purchase inventory in Lensar proper now?
Before you purchase inventory in Lensar, contemplate this:
The Motley Idiot Inventory Advisor analyst workforce simply recognized what they consider are the 10 best stocks for traders to purchase now… and Lensar wasn’t one in all them. The ten shares that made the lower might produce monster returns within the coming years.
Think about when Netflix made this record on December 17, 2004… if you happen to invested $1,000 on the time of our advice, you’d have $463,900!* Or when Nvidia made this record on April 15, 2005… if you happen to invested $1,000 on the time of our advice, you’d have $1,294,401!*
Now, it’s price noting Inventory Advisor’s complete common return is 978% — a market-crushing outperformance in comparison with 211% for the S&P 500. Do not miss the most recent high 10 record, accessible with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person traders for particular person traders.
*Inventory Advisor returns as of June 1, 2026.
This text is a transcript of this convention name produced for The Motley Idiot. Whereas we try for our Silly Finest, there could also be errors, omissions, or inaccuracies on this transcript. As with all our articles, The Motley Idiot doesn’t assume any accountability on your use of this content material, and we strongly encourage you to do your personal analysis, together with listening to the decision your self and studying the corporate’s SEC filings. Please see our Terms and Conditions for extra particulars, together with our Compulsory Capitalized Disclaimers of Legal responsibility.
The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure policy.
Lensar (LNSR) Q1 2026 Earnings Transcript was initially printed by The Motley Idiot
